(-)-Epigallocatechin gallate (EGCG) prevents isoprenaline-induced cardiac marker enzymes and membrane-bound ATPases.
Intake of tea flavonoids has been reported to reduce the incidence of cardiovascular disease. The present study was undertaken to investigate the preventive effect of (-)epigallocatechin gallate (EGCG) on heart weight, cardiac marker enzymes, membrane-bound ATPases and electrolytes in isoprenaline (ISO)-induced myocardial infarcted (MI) Wistar rats. Rats subcutaneously administered ISO 100 mgkg(-1) at intervals of 24 h for 2 days resulted in significant increases in heart weight and the activities of cardiac marker enzymes such as creatine kinase, creatine kinase-MB, lactate dehydrogenase (LDH), aspartate transaminase and alanine transaminase in serum, and significant decreases in the activities of these enzymes in the myocardium. ISO injection also increased levels of LDH isoenzymes (LDH 1 and LDH 2). The activity of Na+/K+ ATPase was decreased significantly and the activities of Ca2+ and Mg2+ ATPases were increased significantly in ISO-induced MI rats. Furthermore, the levels of potassium were lowered and the levels of sodium and calcium were increased in ISO-induced MI rats. Prior treatment with EGCG (10, 20 and 30 mgkg(-1)) daily for a period of 21 days reduced the effects of ISO on heart weight, activities of cardiac marker enzymes and membrane bound-ATPases and levels of LDH 1 and LDH 2 and electrolytes. Thus, EGCG exhibits beneficial effects on these enzymes and electrolytes. The observed effects may be due to the antioxidant and membrane-stabilizing effects of EGCG in ISO-induced MI rats.
Devika
Periyathambi Thangappan
PT
Department of Biochemistry and Biotechnology, Annamalai University, Tamil Nadu, South India.
Mainzen Prince
Ponnian Staneley
PS
D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002392:Catechin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D006321:Heart / Q000187:drug effects*; D007527:Isoenzymes / Q000097:blood; D007545:Isoproterenol; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D015394:Molecular Structure; D009203:Myocardial Infarction / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D009206:Myocardium / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013237:Stereoisomerism
D015415:Biomarkers; D007527:Isoenzymes; D008565:Membrane Proteins; D002392:Catechin; D007770:L-Lactate Dehydrogenase; C409676:lactate dehydrogenase 2; C409667:lactate dehydrogenase 1; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D000251:Adenosine Triphosphatases; D000254:Sodium-Potassium-Exchanging ATPase; C057580:gallocatechol; D007545:Isoproterenol; D002118:Calcium